Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21441798 | 1.00 | KMT2A (0.74) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL29832139 | 0.85 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL21441790 | 0.85 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL21441769 | 0.85 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL29831613 | 0.85 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL18350635 | 0.84 | KMT2A (0.70) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL19646148 | 0.82 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL2988108 | 0.80 | MEN1 (0.82) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL2988105 | 0.80 | MEN1 (0.82) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL21441763 | 0.80 | MEN1 (0.68) | KMT2AMEN1NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774770-B1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | UNIV BRETAGNE OCCIDENTALE (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | UNIVERSITE DE BRETAGNE OCCIDENTALE | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | RB1, MALT1, NR3C1 | KMT2A 965/4885MEN1 401/4885NPC1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.